Drug Profile
Research programme: bispecific antibody therapeutics - Chinook Therapeutics/Genmab
Alternative Names: Immune checkpoint inhibitors - Chinook Therapeutics/GenmabLatest Information Update: 18 Aug 2023
Price :
$50
*
At a glance
- Originator BioNovion; Genmab
- Developer Aduro BioTech; Genmab
- Class Bispecific antibodies
- Mechanism of Action Immune checkpoint protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer